Skip to nav Skip to content
Yehuda  Deutsch

Yehuda Deutsch, MD

Specialty: Hematology/Oncology

Program: Malignant Hematology and Cellular Therapy at Memorial Healthcare System

Language(s): English

  • Overview

    Cancer Focus:
    Hodgkin Lymphoma, Leukemia, MDS, Multiple Myeloma-Plasma Cell Tumor, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

    Dr. Yehuda Deutsch is an assistant member of Moffitt Malignant Hematology and Cellular Therapy at Memorial Healthcare System in Pembroke Pines. He is a board-certified hematologist-oncologist dedicated to improving care of patients with cancer. He grew up in South Florida and earned his medical degree from the University of Miami Miller School of Medicine, where he was elected into the national Alpha Omega Alpha Honor Medical Society. He completed his residency and fellowship at Jackson Memorial Hospital and the University of Miami, where he was the recipient of the Peter A. Cassileth award for outstanding clinical judgment, enthusiasm for learning and compassionate care. Dr. Deutsch has a special focus in hematologic malignancies, including leukemia, lymphoma and myeloma. He is dedicated to improving patient care through teaching and clinical research. Dr. Deutsch was selected to participate in the International Methods in Clinical Cancer Research Workshop, where he advanced his interest in experimental therapeutics of leukemia. He continues to serve as clinical investigator in numerous clinical trials. He has numerous publications and has given presentations at both local and international meetings.

    Education & Training

    Board Certification:

    • Internal Medicine - Hematology


    • Jackson Memorial Hospital - Hematology/Oncology


    • Jackson Memorial Hospital - Internal Medicine

    Medical School:

    • University of Miami Miller School of Medicine - MD
  • Participating Trials

    Clinical Trial 23104
    A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML
    Condition: Malignant Hematology
    Status: Open (affiliates only)

    Clinical Trial 90038
    A Phase 1/2, Multicenter, Open-Label, Single Arm, Dose Escalation and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients with Newly Diagnosed FLT3 mutated Acute Myeloid Leukemia (AML) not Eligible for Intensive Induction Chemotherapy
    Condition: Malignant Hematology
    Status: Open (affiliates only)

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Chan O, Al Ali NH, Tashkandi H, Ellis A, Ball S, Grenet J, Hana C, Deutsch Y, Zhang L, Hussaini MO, Song J, Yun S, Talati C, Kuykendall AT, Padron E, Walker AR, Roboz GJ, Desai P, Sallman DA, Sweet KL, Komrokji RS, Lancet JE. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML. Blood Adv. 2024 Mar.8(5):1075-1083. Pubmedid: 38170740. Pmcid: PMC10907389.
    • Lee D, Jain AG, Deutsch Y, Eatrides J, Chan O, Padron E, Kuykendall A, Komrokji R, Lancet J, Sallman D, Talati C, Sweet K. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2022 Oct.22(10):774-779. Pubmedid: 35760672.
    • Ball S, Knepper TC, Deutsch YE, Samra W, Watts JM, Bradley TJ, Chan O, Hussaini MO, Zhang L, Sweet KL, Kuykendall AT, Talati C, Padron E, Komrokji RS, Lancet JE, Sallman DA. Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations. Cancer. 2022 Nov.128(21):3880-3887. Pubmedid: 36107670.
    • Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf JP, Collins C, Barth D, Fraga M, Bixby DL, Zeidan AM, Yilmaz M, Desai P, Mannis G, Deutsch YE, Abaza Y, Dinner S, Frankfurt O, Litzow M, Al-Kali A, Foran JM, Sproat LZ, Jovanovic B, Daver N, Perl AE, Altman JK. Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors. Am J Hematol. 2022 Mar.97(3):322-328. Pubmedid: 34981560.
    • Stover AM, Urick BY, Deal AM, Teal R, Vu MB, Carda-Auten J, Jansen J, Chung AE, Bennett AV, Chiang A, Cleeland C, Deutsch Y, Tai E, Zylla D, Williams LA, Pitzen C, Snyder C, Reeve B, Smith T, McNiff K, Cella D, Neuss MN, Miller R, Atkinson TM, Spears PA, Smith ML, Geoghegan C, Basch EM. Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers. JCO Oncol Pract. 2020 Mar.16(3):e234-e250. Pubmedid: 32074014. Pmcid: PMC7069703.
    • Sandoval-Sus JD, Brahim A, Khan A, Deutsch Y, Raphael B, Ansari-Lari A, Fernandez HF, Raez LE. Complete Response of Primary Refractory ALK-Positive Large B-Cell Lymphoma Treated With Single-Agent Nivolumab. Clin Lymphoma Myeloma Leuk. 2020 Mar.20(3):e113-e117. Pubmedid: 32033930.
    • Swords RT, Azzam D, Al-Ali H, Lohse I, Volmar CH, Watts JM, Perez A, Rodriguez A, Vargas F, Elias R, Vega F, Zelent A, Brothers SP, Abbasi T, Trent J, Rangwala S, Deutsch Y, Conneally E, Drusbosky L, Cogle CR, Wahlestedt C. Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study. Leuk Res. 2018 Jan.64:34-41. Pubmedid: 29175379. Pmcid: PMC5756519.
    • Berebichez-Fridman R, Deutsch YE, Joyal TM, Olvera PM, Benedetto PW, Rosenberg AE, Kett DH. Stewart-Treves Syndrome: A Case Report and Review of the Literature. Case Rep Oncol. 2016 Apr.9(1):205-211. Pubmedid: 27099606. Pmcid: PMC4836142.
    • Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, Pegram MD, Glück S. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Res Treat. 2012 Feb.132(1):215-223. Pubmedid: 22138748. Pmcid: PMC3697917.
    • Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. 2011 Sep.52(9):1641-1654. Pubmedid: 21619423.
  • Patient Comments

    Overall Satisfaction


    0 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor